DRAXXIN Receives New Label Claim for Treatment of Pink Eye

NEW YORK (March 14, 2008) – DRAXXIN^® (tulathromycin) Injectable Solution is now approved for the treatment of infectious bovine keratoconjunctivitis, commonly known as pink eye, associated with Moraxella bovis in beef and non-lactating dairy cattle.

The Food and Drug Administration approved the claim after reviewing research that showed a single dose of DRAXXIN was effective against pink eye associated with Moraxella bovis.¹

Not only can pink eye be frustrating, it can also be economically damaging. Dusty conditions, bright sunlight and fly infestations contribute to its spread. And slowed growth rate and increased handling are all additional costs resulting from this very contagious and damaging disease. In fact, pink eye can cost U.S. cattle producers up to $150 million per year.²

DRAXXIN is also the only antibiotic approved for the treatment and control in cattle at high risk of developing bovine respiratory disease (BRD), also known as calf pneumonia, associated with all four major BRD bacterial pathogens: Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. This leader in BRD therapy now provides producers with even more benefits.

It is available in four sizes (50-, 100-, 250-, 500-mL) to meet the needs of any operation. Always follow label instructions to ensure proper use of the product.

For more information about DRAXXIN, talk to your veterinarian or Pfizer Animal Health representative. Do not use in female dairy cattle. Do not use in animals known to be hypersensitive to the product. Do not use in calves to be processed for veal. A withdrawal time has not been established for this product in pre-ruminating calves. DRAXXIN has a pre-slaughter withdrawal time of 18 days. Visit draxxin.com for full prescribing information.